Objectives: Investigate the management and outcomes of patients diagnosed with squamous cell carcinoma of the ovary (SCC-O). Methods: Patients with no history of another tumor diagnosed between 2004-2015 with SCC-O, known tumor stage and at least one month of follow-up were drawn from the National Cancer Database. Clinico-pathological and demographic characteristics were analyzed and overall survival (OS) was evaluated following generation of Kaplan-Meier curves. A Cox model was constructed to evaluate for independent predictors of survival. Results: A total of 440 patients with a median age of 53 years (range 15-90) were identified; 34.3% had stage I disease, while 19.5%, 26.8% and 19.3% had stage II, III and IV disease respectively. Most patients were White (72%) without co-morbidities (82%). Median tumor size was 9.5 cm while tumor grade was available for 370 cases; 52.4% had grade 3 tumors while 39.2% and 8.4% had grade 2 and 1 tumors respectively. Based on 87 patients with apparent early stage disease who underwent lymphadenectomy, lymph node involvement was rare (2%). Five-year OS rate for patients with stage I disease was 75.8% compared to 28.5%, 29.3% and 11.6% for those with stage II, III, IV disease, p<0.001. Among patients with stage I disease, 5-yer OS rate for those with stage IA (n=101) was 83% compared to 63.5% for those with stage IC disease (n=42), p=0.039. By multivariate analysis, performance of LND and administration of chemotherapy were not associated with a survival benefit, while stage IC (HR: 2.53) was associated with worse survival. For patients with advanced stage disease (II-IV) administration of chemotherapy was associated with a survival benefit (median OS 13.63 vs 6.9, p=0.01) while administration of radiation therapy (n=61) was not (p=0.14). Based on 87 patients with advanced stage disease (II-IV) and available data on residual disease status, achieving complete gross resection was associated only with small survival benefit (median OS 14.92 vs 10.25 months, p=0.065). Conclusions: SCC-O is a rare tumor with a poor prognosis especially for patients with advanced stage disease. Novel treatment options are greatly warranted. Investigate the management and outcomes of patients diagnosed with squamous cell carcinoma of the ovary (SCC-O). Patients with no history of another tumor diagnosed between 2004-2015 with SCC-O, known tumor stage and at least one month of follow-up were drawn from the National Cancer Database. Clinico-pathological and demographic characteristics were analyzed and overall survival (OS) was evaluated following generation of Kaplan-Meier curves. A Cox model was constructed to evaluate for independent predictors of survival. A total of 440 patients with a median age of 53 years (range 15-90) were identified; 34.3% had stage I disease, while 19.5%, 26.8% and 19.3% had stage II, III and IV disease respectively. Most patients were White (72%) without co-morbidities (82%). Median tumor size was 9.5 cm while tumor grade was available for 370 cases; 52.4% had grade 3 tumors while 39.2% and 8.4% had grade 2 and 1 tumors respectively. Based on 87 patients with apparent early stage disease who underwent lymphadenectomy, lymph node involvement was rare (2%). Five-year OS rate for patients with stage I disease was 75.8% compared to 28.5%, 29.3% and 11.6% for those with stage II, III, IV disease, p<0.001. Among patients with stage I disease, 5-yer OS rate for those with stage IA (n=101) was 83% compared to 63.5% for those with stage IC disease (n=42), p=0.039. By multivariate analysis, performance of LND and administration of chemotherapy were not associated with a survival benefit, while stage IC (HR: 2.53) was associated with worse survival. For patients with advanced stage disease (II-IV) administration of chemotherapy was associated with a survival benefit (median OS 13.63 vs 6.9, p=0.01) while administration of radiation therapy (n=61) was not (p=0.14). Based on 87 patients with advanced stage disease (II-IV) and available data on residual disease status, achieving complete gross resection was associated only with small survival benefit (median OS 14.92 vs 10.25 months, p=0.065). SCC-O is a rare tumor with a poor prognosis especially for patients with advanced stage disease. Novel treatment options are greatly warranted.